Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
暂无分享,去创建一个
D. Ferrero | R. Freilone | M. Cerrano | M. Olivi | E. Audisio | V. Giai | Chiara Frairia | Giulia Arrigo | I. Urbino | S. D'ardia | Carolina Secreto | Marco Cerrano | Eleonora Boscaro | Irene Urbino | Federica Maria Catania | Giulia Arrigo | Carolina Secreto | Matteo Olivi | Stefano D’Ardia | Chiara Frairia | Valentina Giai | Roberto Freilone | Dario Ferrero | Ernesta Audisio | Eleonora Boscaro | Federica Maria Catania | S. D’ardia | F. Catania | E. Boscaro | G. Arrigo | C. Frairia
[1] H. Dombret,et al. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study , 2023, Blood advances.
[2] N. Potter,et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial , 2023, Blood advances.
[3] Deborah A. Freedman-Cass,et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. , 2023, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] W. Hiddemann,et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia , 2023, Leukemia.
[5] M. Konopleva,et al. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) , 2023, Haematologica.
[6] G. Priolo,et al. Validation of National Early Warning Score and Quick Sequential (sepsis‐related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy , 2023, European journal of haematology.
[7] Yi-Kuang Chuang,et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia , 2023, American journal of hematology.
[8] K. Mrózek,et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study , 2023, Leukemia.
[9] R. Ries,et al. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Dombret,et al. Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis , 2023, Annals of Hematology.
[11] M. Levis,et al. The clinical impact of the molecular landscape of acute myeloid leukemia , 2023, Haematologica.
[12] A. Busca,et al. Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis , 2023, Cancers.
[13] M. Tormo,et al. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry , 2023, Cancers.
[14] G. Stefanzl,et al. N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia , 2023, American journal of hematology.
[15] G. Borthakur,et al. The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation , 2022, Cancers.
[16] R. Walter,et al. Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia , 2022, Cancers.
[17] E. Clappier,et al. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively , 2022, HemaSphere.
[18] R. Schlenk,et al. Overlapping features of therapy-related and de novoNPM1-mutated AML. , 2022, Blood.
[19] J. Capo-Chichi,et al. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. , 2022, Leukemia research.
[20] C. Hourigan,et al. The present and future of measurable residual disease testing in acute myeloid leukemia , 2022, Haematologica.
[21] D. Bottomly,et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia , 2022, Blood advances.
[22] L. Mannone,et al. Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia , 2022, Cancer medicine.
[23] J. E. Butler,et al. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance , 2022, Blood.
[24] T. Haferlach,et al. A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia , 2022, Blood.
[25] H. Döhner,et al. ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine , 2022, Blood.
[26] E. Estey,et al. Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification , 2022, Blood.
[27] H. Dombret,et al. Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group , 2022, Blood.
[28] J. Soulier,et al. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] E. Clappier,et al. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML , 2022, Blood Cancer Journal.
[30] L. Möllgård,et al. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications , 2022, Haematologica.
[31] A. Tantiworawit,et al. Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group. , 2022, Clinical lymphoma, myeloma & leukemia.
[32] F. Ferrara,et al. MRD in Venetoclax-Based Treatment for AML: Does it Really Matter? , 2022, Frontiers in Oncology.
[33] U. Platzbecker,et al. Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation , 2022, American journal of hematology.
[34] B. Ebert,et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.
[35] M. Loh,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.
[36] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[37] E. Clappier,et al. A multiparametric niche-like drug screening platform in acute myeloid leukemia , 2022, Blood Cancer Journal.
[38] J. Soulier,et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. , 2022, Blood.
[39] P. Campbell,et al. Unified classification and risk-stratification in Acute Myeloid Leukemia , 2022, Nature Communications.
[40] J. Cox,et al. The proteogenomic subtypes of acute myeloid leukemia. , 2022, Cancer cell.
[41] M. Konopleva,et al. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy , 2022, Blood advances.
[42] M. Jongen‐Lavrencic,et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome , 2022, Blood.
[43] A. Berghold,et al. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations , 2022, Annals of Hematology.
[44] P. D. Dal Cin,et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.
[45] B. Cho,et al. Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML. , 2022, Blood.
[46] H. Döhner,et al. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Gentles,et al. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia , 2021, Nature Communications.
[48] A. Letai,et al. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. , 2021, Cancer cell.
[49] J. Byrd,et al. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia , 2021, Blood advances.
[50] R. Ries,et al. CREBBP Alterations are Associated with A Poor Prognosis in de novo AML. , 2021, Blood.
[51] R. Schlenk,et al. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 , 2021, Haematologica.
[52] K. Döhner,et al. 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.
[53] A. Busca,et al. Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021 , 2021, Cancers.
[54] R. Itzykson,et al. Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias , 2021, Cancers.
[55] H. Einsele,et al. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. , 2021, Blood advances.
[56] J. Kanda,et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia , 2021, Blood advances.
[57] R. Schlenk,et al. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study , 2021, Haematologica.
[58] H. Einsele,et al. CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. , 2021, Blood.
[59] C. Bloomfield,et al. Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement , 2021, Journal of Hematology & Oncology.
[60] H. Dombret,et al. Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy. , 2021, Blood.
[61] C. Bloomfield,et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). , 2021, Blood advances.
[62] H. Kantarjian,et al. De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 , 2021, Cancer.
[63] H. Dombret,et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. , 2021, Blood.
[64] E. Estey,et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study * , 2021, British journal of haematology.
[65] M. Voso,et al. From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression , 2021, Biology.
[66] F. Pasquier,et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. , 2021, Blood advances.
[67] M. Konopleva,et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. , 2020, Blood advances.
[68] M. Konopleva,et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. , 2020, Blood advances.
[69] J. Bourhis,et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. , 2020, Blood.
[70] A. Abate,et al. Single cell mutation analysis of clonal evolution in myeloid malignancies , 2020, Nature.
[71] M. Shah,et al. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia , 2020, Genes.
[72] J. Soulier,et al. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy , 2020, Leukemia.
[73] H. Kantarjian,et al. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia , 2020, Leukemia.
[74] A. Bagg,et al. Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study , 2020, American journal of hematology.
[75] E. Estey,et al. Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. , 2020, Blood reviews.
[76] W. Hiddemann,et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia , 2020, Leukemia.
[77] T. Haferlach,et al. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. , 2020, Blood.
[78] A. Ganser,et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia , 2020, Blood Cancer Journal.
[79] P. A. Futreal,et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics , 2020, Nature Communications.
[80] J. Esteve,et al. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission , 2020, British journal of haematology.
[81] S. Saad,et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. , 2020, Blood.
[82] T. Naoe,et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. , 2020, Blood advances.
[83] W. Hiddemann,et al. The clinical mutatome of core binding factor leukemia , 2020, Leukemia.
[84] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[85] C. Bloomfield,et al. Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.
[86] R. Aplenc,et al. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. , 2019, Current opinion in pediatrics.
[87] C. Dinardo,et al. How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.
[88] H. Dombret,et al. Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis , 2019, Leukemia & lymphoma.
[89] Verena I Gaidzik,et al. Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group. , 2019, Blood.
[90] T. Haferlach,et al. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. , 2019, Cancer genetics.
[91] E. Estey,et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] C. Bloomfield,et al. Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia , 2019, Haematologica.
[93] G. Ossenkoppele,et al. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. , 2019, Critical reviews in oncology/hematology.
[94] X. Ke,et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia , 2019, Journal of Hematology & Oncology.
[95] E. Estey,et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.
[96] S. Wetten,et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia , 2019, Haematologica.
[97] L. Bullinger,et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. , 2019, Blood.
[98] M. Sanders,et al. The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome , 2019, HemaSphere.
[99] A. Stamatoullas,et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure , 2019, Haematologica.
[100] R. Itzykson,et al. New Treatment Options for Acute Myeloid Leukemia in 2019 , 2019, Current Oncology Reports.
[101] C. Bloomfield,et al. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically , 2019, Leukemia.
[102] Alice Giustacchini,et al. Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing , 2019, Molecular cell.
[103] E. Hoster,et al. Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. , 2018, Blood advances.
[104] Beth Wilmot,et al. Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.
[105] G. Salles,et al. Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. , 2018, Blood.
[106] Stanley W. K. Ng,et al. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia , 2018, Leukemia.
[107] Hong-jie Shen,et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia , 2018, Haematologica.
[108] H. Dombret,et al. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. , 2018, Blood.
[109] B. Ko,et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor‐risk factor in de novo acute myeloid leukemia patients , 2018, European journal of haematology.
[110] T. Graubert,et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. , 2018, Blood.
[111] B. Dörken,et al. BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease? , 2018, Blood advances.
[112] H. Kantarjian,et al. Response kinetics and factors predicting survival in core-binding factor leukemia , 2018, Leukemia.
[113] J. Li,et al. Long noncoding RNA SNHG5 is up-regulated and serves as a potential prognostic biomarker in acute myeloid leukemia. , 2018, European review for medical and pharmacological sciences.
[114] J. Welch,et al. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[115] B. Ko,et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA , 2018, Haematologica.
[116] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[117] M. Severgnini,et al. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences , 2018, Leukemia.
[118] C. Bloomfield,et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies , 2018, Leukemia.
[119] J. Esteve,et al. Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT) , 2018, American journal of hematology.
[120] M. Andreeff,et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. , 2017, Blood advances.
[121] M. Konopleva,et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. , 2017, Blood advances.
[122] E. Clappier,et al. The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.
[123] J. Bourhis,et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT , 2017, American journal of hematology.
[124] Lars Bullinger,et al. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] G. Wertheim,et al. Validation of a clinical assay of multi‐locus DNA methylation for prognosis of newly diagnosed AML , 2017, American journal of hematology.
[126] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[127] B. Wood,et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis , 2017, Haematologica.
[128] Inigo Martincorena,et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.
[129] J. Tchinda,et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups , 2016, Cancer.
[130] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[131] M. Heuser. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? , 2016, Hematology. American Society of Hematology. Education Program.
[132] J. Manola,et al. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] W. Hiddemann,et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.
[134] E. Ma,et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome , 2016, Blood Cancer Journal.
[135] G. Wertheim,et al. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. , 2016, JCI insight.
[136] Francine E. Garrett-Bakelman,et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia , 2016, Nature Medicine.
[137] B. Dörken,et al. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features , 2016, Annals of Hematology.
[138] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[139] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[140] H. Kestler,et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features , 2016, Leukemia.
[141] Li Chen,et al. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis , 2016, PloS one.
[142] D. Blaise,et al. Hematopoietic stem cell transplantation for patients with AML in first complete remission. , 2016, Blood.
[143] D. Grimwade,et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.
[144] H. Einsele,et al. Karyotype complexity and prognosis in acute myeloid leukemia , 2016, Blood Cancer Journal.
[145] D. Johnston,et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] B. Johansson,et al. Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia , 2015, American journal of hematology.
[147] M. Nørgaard,et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[148] H. Dombret,et al. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group , 2015, Cancer.
[149] Sean C. Bendall,et al. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.
[150] D. Neuberg,et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.
[151] J. Cayuela,et al. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia , 2014, Haematologica.
[152] Guido Marcucci,et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia , 2014, Proceedings of the National Academy of Sciences.
[153] S. Raimondi,et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3‐ITD status: a report from the Children's Oncology Group , 2014, British journal of haematology.
[154] Guido Marcucci,et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] F. Dignan,et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML , 2014, Bone Marrow Transplantation.
[156] J. Esteve,et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia , 2014, Leukemia.
[157] Pearlly Yan,et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[158] S. Miyano,et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients , 2014, Leukemia.
[159] B. Johansson,et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience , 2014, Blood Cancer Journal.
[160] R. Hills,et al. Hyperdiploidy with 49–65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome , 2014, Leukemia.
[161] T. Brümmendorf,et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia , 2013, Leukemia.
[162] A. Jauch,et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[163] E. Estey,et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.
[164] Guido Marcucci,et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[165] M. Gobbi,et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making , 2013, Leukemia.
[166] J. Cayuela,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.
[167] L. Bullinger,et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). , 2013, Blood.
[168] Wolfgang Hiddemann,et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes , 2012, Haematologica.
[169] A. Letai,et al. Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.
[170] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[171] K. Coombes,et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. , 2012, Blood.
[172] E. Hoster,et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. , 2012, Blood.
[173] P. Mintz,et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. , 2012, Blood reviews.
[174] T. Haferlach,et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. , 2012, Blood.
[175] Bob Löwenberg,et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value , 2012, Haematologica.
[176] K. Mrózek,et al. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. , 2011, Hematology/oncology clinics of North America.
[177] K. Döhner,et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. , 2011, Blood.
[178] Angelo J. Canty,et al. Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.
[179] K. Wagner,et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[180] H. Kantarjian,et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia , 2011, Cancer.
[181] Erdogan Taskesen,et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.
[182] Joshua F. McMichael,et al. DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.
[183] M. Caligiuri,et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.
[184] F. Appelbaum,et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. , 2010, Blood.
[185] K. Döhner,et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[186] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[187] M. Nelson,et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. , 2010, Blood.
[188] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[189] A. Kohlmann,et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.
[190] H. Dombret,et al. Brief Report Results and Discussion , 2022 .
[191] L. Bullinger,et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.
[192] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[193] A. Kohlmann,et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features , 2009, Leukemia.
[194] Ulrich Mansmann,et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. , 2008, Blood.
[195] A. Hagemeijer,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[196] M. Caligiuri,et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[197] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[198] M. Caligiuri,et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[199] T. Haferlach,et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. , 2008, Blood.
[200] A. Mead,et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. , 2007, Blood.
[201] C. Bloomfield,et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[202] H. Dombret,et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.
[203] Gerhard Ehninger,et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.
[204] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[205] Torsten Haferlach,et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile , 2005, Genes, chromosomes & cancer.
[206] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[207] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[208] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[209] A. Venditti,et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.
[210] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[211] B. Branger,et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival , 2002, British journal of haematology.
[212] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .
[213] M. McMullin,et al. High bax expression is a good prognostic indicator in acute myeloid leukaemia , 2000, British journal of haematology.
[214] O. Legrand,et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. , 1998, Blood.
[215] W. Hiddemann,et al. A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients , 2018, Leukemia.
[216] Jong-Ho Won,et al. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[217] N. Schmitz,et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome , 2013, Leukemia.
[218] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[219] Gordon B Mills,et al. Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.
[220] W. Hiddemann,et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.
[221] A. Venditti,et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. , 2004, Haematologica.
[222] K. Farkas. Acute Myeloid Leukemia , 1958, Orvosi Hetilap.